Drug Profile
Miconazole - Hill Dermaceuticals
Alternative Names: MiconzoleLatest Information Update: 30 Jan 2024
Price :
$50
*
At a glance
- Originator Hill Dermaceuticals
- Class Antifungals; Imidazoles; Small molecules
- Mechanism of Action 14-alpha demethylase inhibitors; Cell membrane modulators; Cholesterol synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Otomycosis
Most Recent Events
- 21 Dec 2022 Hill Dermaceuticals plans a phase III trial for Otomycosis in May 2023 (NCT05660382)
- 29 Nov 2022 No development reported - Phase-II/III for Otomycosis (In adolescents, In children, In the elderly, In adults) in USA (Otic) (Hill Dermaceuticals pipeline, November 2022)
- 08 Jul 2020 Phase-II/III clinical trials in Otomycosis (In adolescents, In children, In the elderly, In adults) in USA (Otic) (NCT04432376)